CaptureRx Co-founder Steps Down as its President to Run the Washington, DC Based Non-Profit 340B Best Practices User Group - Medicine Access & Compliance Coalition™

WASHINGTON, Sept. 19, 2013 /PRNewswire/ -- In an effort to maintain integrity and focus on the initiatives of the Medicine Access & Compliance Coalition™, also known as MACC, Edward Gilmartin, co-founder of one of the nation's largest 340B administrators, CaptureRx®, has temporarily stepped down as its president as of September 9^th.  Although Mr. Gilmartin may not be managing day-to-day operations at CaptureRx®, he will be working in a consultative fashion on broad concepts and industry trends.

MACC was recently launched in late July of this year and is the first and single largest 340B drug program user group of its kind to voluntarily submit to self-examination through peer and industry review, seeking constructive input from drug manufacturers, legislators and other advocacy groups to produce and promote recommended best practices. MACC also has the distinction of being one of the first groups to include joint Federally Qualified Health Center (FQHC) and hospital leadership, with its co-chairs including the Honorable Billy Tauzin, former U.S. Congressman and past President of the Pharmaceutical Research and Manufacturers of America (PhRMA), and Dean Germano, CEO of Shasta Community Health Center of Redding, California.

Since MACC's formation, it has established offices in Washington, DC, and hired an Associate Director, who will manage MACC's daily functions and policy initiatives along with Mr. Gilmartin, who will also be working and living in DC. 

This Fall, MACC will be focused on creating a set of standards and 340B best practices that its members can follow for the newly created MACC Certification Program. These "MACC Standards" will be developed and approved by a Standards Review Board comprised of MACC Covered Entity Members and outside stakeholders to include pharma, bio, PBM, chain and independent pharmacy vendors, to name a few.

"We are receiving positive feedback from both pharma and bio companies already," states Mr. Gilmartin, MACC's new President. Mr. Gilmartin adds, "Pharma companies are realizing that they have a lot more in common with MACC than they thought." MACC will be announcing more solutions that they believe will be received very well by the pharma and bio industries, and that will protect the integrity and longevity of the 340B program for safety net providers. 

About MACC

MACC represents safety-net clinics and hospitals that use the 340B drug program compliance technology platform called CUMULUS™, a CaptureRx® solution.  The user group consists of over 1,500 covered entity site locations, operating in 42 states and managing over 5.2 million patient lives with 20 million outpatient medical encounters annually.

MACC core initiatives shall: 1) create standards and best practices with oversight and third party audit activities to assure compliance, transparency and stewardship of the 340B pharmacy medicine discount program; 2) promote and deploy medicine therapies, adherence and education programs to the most vulnerable patient populations mostly served by safety-net providers; and 3) assist in defining policy and advocating for medicine access through open dialogue with industry stakeholders, regulators and legislators. For more information on MACC, please visit www.medicineaccess.org.

For Information Contact:
Chris Kapsch
Associate Director, MACC
202-733-2636
[email protected]

SOURCE Medicine Access & Compliance Coalition